Skip to content

KNSA KINIKSA PHARMACEUTICALS INTL

Follow

Stock (common), issuer CIK 1730430

Filings received so far for Q3 2026: 10 13F filers report a position in KNSA shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.

13D and 13G filers

No 13D or 13G on this security in the data. Structured 13D/G data starts 2024-12-18.

Insider trades

No Form 4 transaction on this security in the data.

13F holders, Q3 2026

Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.

HolderSharesValue% of portfolioChangeSource
Timothy G. Youngquist 2020 Irrevocable …34,341$2.56M0.51%013F-HRTimeline
TOTH FINANCIAL ADVISORY CORP20,825$1.55M0.16%+10013F-HRTimeline
JUNCTURE WEALTH STRATEGIES, LLC17,549$1.31M0.34%-27513F-HRTimeline
City Center Advisors, LLC5,271$393K0.3%new13F-HRTimeline
CoreCap Advisors, LLC4,620$345K0.01%new13F-HRTimeline
Farther Finance Advisors, LLC1,491$111K<0.01%-12613F-HRTimeline
GAMMA Investing LLC1,278$95.4K<0.01%+22313F-HRTimeline
True Wealth Design, LLC689$51.4K0.01%+213F-HRTimeline
Versant Capital Management, Inc186$13.9K<0.01%+2013F-HRTimeline
MassMutual Private Wealth & Trust, FSB3$224<0.01%new13F-HRTimeline